# Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

> **NCT00369317** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 205 (actual)

## Conditions studied

- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- Childhood Acute Megakaryocytic Leukemia (M7)
- Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
- Childhood Acute Monoblastic Leukemia (M5a)
- Childhood Acute Monocytic Leukemia (M5b)
- Childhood Acute Myeloblastic Leukemia With Maturation (M2)
- Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
- Childhood Acute Myelomonocytic Leukemia (M4)
- Childhood Myelodysplastic Syndromes
- de Novo Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndromes
- Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

## Interventions

- **DRUG:** asparaginase
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** cytarabine
- **DRUG:** thioguanine
- **DRUG:** etoposide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00369317
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2013-12-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2022-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369317, "Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00369317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*